Quantitative dynamic nuclear polarization-NMR on blood plasma for assays of drug metabolism

NMR in Biomedicine

Volumn 24, Issue 1, 2011, Pages 96-103

  Lerche, Mathilde H ^a   Meier, Sebastian ^b   Jensen, Pernille R ^a   Hustvedt, Svein Olaf ^c   Karlsson, Magnus ^a   Duus, Jens Ø ^b   Ardenkjær Larsen, Jan H ^d  

^a Albeda Research   (Denmark)

^b CARLSBERG LABORATORY   (Denmark)

^c GE HEALTHCARE   (Norway)

^d GE HEALTHCARE   (United States)

Author keywords

13C NMR; Blood plasma; Carbamazepine; DNP NMR; Drug metabolism; Therapeutic drug monitoring

Indexed keywords

13C NMR; BLOOD PLASMA; CARBAMAZEPINE; DNP-NMR; DRUG METABOLISMS; THERAPEUTIC DRUG MONITORING;

AMIDES; ASSAYS; BIOMOLECULES; BLOOD; CORRELATION METHODS; DISSOLUTION; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; METABOLISM; METABOLITES; PATIENT MONITORING; PLASMAS; SPIN POLARIZATION;

NUCLEAR MAGNETIC RESONANCE;

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DILTIAZEM;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DERIVATIZATION; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; DYNAMIC NUCLEAR POLARIZATION NUCLEAR MAGNETIC RESONANCE; DYNAMICS; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PLASMA; POLARIZATION; PRECIPITATION; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

ANIMALS; BIOLOGICAL ASSAY; CALIBRATION; CARBAMAZEPINE; CHROMATOGRAPHY, LIQUID; DRUG INTERACTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PLASMA; RABBITS; REFERENCE STANDARDS;

ORYCTOLAGUS CUNICULUS;

EID: 78851470658     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1561     Document Type: Article

References (47)

1. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003; 348: 538-549.
2. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003; 348: 529-537.
3. Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. Br. J. Clin. Pharmacol. 2001; 52 (Suppl 1): 11S-20S.
4. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 2003; 25: 347-363.
5. Robertson DG. Metabonomics in toxicology: a review. Toxicol. Sci. 2005; 85: 809-822.
6. 13C NMR spectroscopy of urine for metabonomic studies. Anal. Chem. 2002; 74: 4588-4593.
7. 13C label-nuclear magnetic resonance (NMR) tracer techniques to clinical chemistry. Metabolic rate of benzoic acid to hippuric acid]. Yakugaku Zasshi, 1990; 110: 586-590.
8. 13C-labeling and nuclear magnetic resonance spectroscopy to pharmacokinetic research: measurement of metabolic rate of benzoic acid to hippuric acid in the rat. Anal. Biochem. 1993; 210: 86-90.
9. Akira K, Negishi E, Imachi M, Hashimoto T. Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine. Drug Metab. Dispos. 2001; 29: 903-907.
10. Akira K, Negishi E, Sakuma C, Hashimoto T. Direct detection of antipyrine metabolites in rat urine by (13)C labeling and NMR spectroscopy. Drug Metab. Dispos. 1999; 27: 1248-1253.
11. Mills GA, Walker V. Headspace solid-phase microextraction profiling of volatile compounds in urine: application to metabolic investigations. J. Chromatogr. B: Biomed. Sci. Appl. 2001; 753: 259-268.
12. Abragam A, Goldman M. Principles of dynamic nuclear polarisation. Rep. Progr. Phys. 1978; 41: 395-467.
13. Ardenkjær-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thanning M, Golman K. Increase in signal-to-noise ratio of>10, 000 times in liquid-state NMR. Proc. Natl. Acad. Sci. USA, 2003; 100: 10, 158-10, 163.
14. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab. Dispos. 2008; 36: 490-499.
15. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 2002; 30: 1170-1179.
16. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem. Pharmacol. 1994; 47: 1969-1979
17. Svinarov DA, Pippenger CE. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. Ther. Drug Monit. 1996; 18: 660-665.
18. Morselli PL, Frigerio A. Metabolism and pharmacokinetics of carbamazepine. Drug Metab. Rev. 1975; 4: 97-113.
19. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab. Dispos. 2005; 33: 644-648.
20. Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int. J. Clin. Pharmacol. Ther. 1998; 36: 306-308.
21. Birkett DJ. Therapeutic drug monitoring. Austral. Prescriber, 1997; 20: 9.
22. Jensen PR, Karlsson M, Meier S, Duus JØ, Lerche MH. Hyperpolarized amino acids for in vivo assays of transaminase activity. Chem. A Euro. J., 2009; 15: 10010-10012.
23. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magma, 2001; 12: 141-152.
24. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 2004; 32: 647-660.
25. Abdel-Hamid ME. Comparative LC-MS and HPLC analyses of selected antiepileptics and beta-blocking drugs. Il Farmaco, 2000; 55: 136-145.
26. 13C]pyruvic acid at 4.6 tesla. J. Magn. Reson. 2009; 197: 167-175.
27. Lerche MH, Meier S, Jensen PR, Baumann H, Petersen BO, Karlsson M, Duus JO, Ardenkjaer-Larsen JH. Study of molecular interactions with (13)C DNP-NMR. J. Magn. Reson. 2009; 203: 52-56.
28. 13C metabolic imaging. 2nd Dynamic Nuclear Polarization Symposium, Königstein, Germany, 2009; 38.
29. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68: 8607-8615.
30. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T - initial experience. Magn. Reson. Med. 2007; 58: 1099-1106.
31. 13C MRSI studies. Magn. Reson. Imaging, 2008; 26: 721-726.
32. 13C-labelled bicarbonate. Nature, 2008; 453: 940-943.
33. Golman K, in't Zandt R, Thanning M. Real-time metabolic imaging. Proc. Natl. Acad Sci USA, 2006; 103: 11, 270-11, 275.
34. 13C MRI. Magn. Reson. Med. 2008; 59: 1005-1013.
35. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006; 66: 10, 855-10, 860.
36. 3. Magn. Reson. Med. 2008; 60: 1029-1036.
37. Schroeder MA, Cochlin LE, Heather LC, Clarke K, Radda GK, Tyler DJ. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc. Natl. Acad. Sci. USA, 2008; 105: 12, 051-12, 056.
38. al-Humayyd MS. Elevation of carbamazepine plasma levels by diltiazem in rabbits: a potentially important drug interaction. Biopharm. Drug Dispos. 1990; 11: 411-417.
39. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. The Lancet Neurology, 2003; 2: 473-481.
40. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet. 1996; 31: 198-214.
41. Potter JM, Donnelly A. Carbamazepine-10, 11-epoxide in therapeutic drug monitoring. Ther. Drug Monit. 1998; 20: 652-657.
42. Ramsay RE, McManus DQ, Guterman A, Briggle TV, Vazquez D, Perchalski R, Yost RA, Wong P. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ther. Drug Monit. 1990; 12: 235-241.
43. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci. 2001; 58: 737-747.
44. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G. The AGNP-TDM expert group consensus guidelines: Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry, 2004; 37: 243.
45. Contin M, Riva R, Albani F, Perucca E, Baruzzi A. Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: interference with the 10, 11-epoxide metabolite. Ther. Drug Monit. 1985; 7: 46-50.
46. Wishart DS. Metabolomics: applications to food science and nutrition research. Trends Food Sci. Technol. 2008; 19: 482-493.
47. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005; 38: 328-334.